Gallieni Maurizio, Olivi Laura, Mezzina Nicoletta, Cozzolino Mario, Cusi Daniele
UO Nefrologia e Dialisi, Ospedale San Carlo Borromeo, Milano.
Recenti Prog Med. 2010 Feb;101(2):70-7.
ACE inhibitors and angiotensin receptor blockers confer renal protection in proteinuric nephropaties, but recently worsening of renal outcomes has been reported in non-proteinuric patients treated with a combination of ramipril and telmisartan, compared to ramipril only. In view of these apparently contradictory data, the review wants to shed light on treatment modalities of patients with hypertension and chronic kidney disease.
血管紧张素转换酶抑制剂（ACE抑制剂）和血管紧张素受体阻滞剂可在蛋白尿性肾病中提供肾脏保护作用，但最近有报道称，与单用雷米普利相比，接受雷米普利和替米沙坦联合治疗的非蛋白尿患者的肾脏结局恶化。鉴于这些明显相互矛盾的数据，本综述旨在阐明高血压和慢性肾脏病患者的治疗方式。
